Clinical Trials Logo

Adenocarcinoma of the Stomach clinical trials

View clinical trials related to Adenocarcinoma of the Stomach.

Filter by:

NCT ID: NCT00982592 Completed - Clinical trials for Adenocarcinoma of the Gastroesophageal Junction

Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer

Start date: September 2009
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies combination chemotherapy when given together with vismodegib to see how well it works compared with combination chemotherapy without vismodegib in treating patients with advanced stomach cancer or gastroesophageal junction cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Vismodegib may stop the growth of stomach or gastroesophageal junction cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether combination chemotherapy is more effective when given with or without vismodegib in treating stomach cancer and gastroesophageal junction cancer.

NCT ID: NCT00871273 Terminated - Clinical trials for Adenocarcinoma of the Stomach

Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma

Start date: November 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics (PK) of capecitabine in patients who have undergone a total gastrectomy.

NCT ID: NCT00607594 Completed - Clinical trials for Adenocarcinoma of the Gastroesophageal Junction

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

Start date: January 2008
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well saracatinib works in treating patients with locally advanced or metastatic stomach or gastroesophageal junction cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00098527 Terminated - Clinical trials for Recurrent Gastric Cancer

FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer

Start date: October 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well FR901228 works in treating patients with refractory stomach cancer or gastroesophageal junction. Drugs used in chemotherapy, such as FR901228, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. FR901228 may also stop the growth of tumor cells by blocking some of the enzymes needed for their growth.

NCT ID: NCT00062374 Completed - Clinical trials for Stage IV Gastric Cancer

Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction

Start date: June 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving irinotecan together with cisplatin works in treating patients who are undergoing surgical resection for locally advanced cancer of the stomach or gastroesophageal junction. Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug and giving them before surgery may shrink the tumor so that it can be removed during surgery.